Document is current
Any future updates will be listed below
-
Authors
de Vries, Sieta T. https://orcid.org/0000-0001-6090-2434
Pena, Michelle J. https://orcid.org/0000-0003-3340-2893
Tye, Sok Cin https://orcid.org/0000-0002-7286-1745
Peters, Sanne A. E. https://orcid.org/0000-0003-0346-5412
van Raalte, Daniël H. https://orcid.org/0000-0003-2894-6124
Arnott, Clare https://orcid.org/0000-0001-9370-9913
Voors, Adriaan A. https://orcid.org/0000-0002-5417-4415
Mol, Peter G. M. https://orcid.org/0000-0002-4262-3180
Denig, Petra https://orcid.org/0000-0002-7929-4739
Heerspink, Hiddo J. L. https://orcid.org/0000-0002-3126-3730
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking & Horizon Europe Research and Innovation Actions (grant agreement No 115974, 101095146)
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 8 October 2024
First Online: 10 December 2024
Data availability statement
: The data used for this study are available upon reasonable request to the corresponding author.
: This study was conducted in the context of the BEAt-DKD project. This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115974. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF. Any dissemination of results reflects only the authors’ view; the JU is not responsible for any use that may be made of the information this study contains. Funding was also obtained from European Union’s HORIZON Research and Innovation Actions (HORIZON-HLTH-2022-TOOL-11-01 - Tools and technologies for a healthy society) undertaking under grant agreement no. 101095146. The views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. SAEP is supported by a Vidi Fellowship from the Dutch Organisation for Health Research and Development (ZonMW) (09150172010050). HJLH is supported by Vidi grant from the Netherlands Organisation for Scientific Research (917.15.306).
: DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Bayer and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca and Merck. CA has received honoraria from Astra Zeneca, Novo Nordisk and Amgen. AAV has acted as a consultant for AnaCardio, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk and Roche Diagnostics. HJLH is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, DImerix, Eli Lilly, Fresenius, Gilead, Janssen, NovoNordisk, Novartis and Travere Therapeutics. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: STdV and MJP contributed to the analyses, to the interpretation of the data and writing of the manuscript. SCT conducted the analyses. SCT, SAEP, DHvR, CA, AAV, PGMM and PD contributed to the interpretation of the data and writing of the manuscript. HJLH provided the data and contributed to the interpretation of the data and writing of the manuscript. All authors read and approved the manuscript. HJLH is responsible for the integrity of the work as a whole.
